University of South Florida

Digital Commons @ University of South Florida
Mathematics and Statistics Faculty
Publications

Mathematics and Statistics

2019

Sex, Age, and BMI Modulate the Association of Physical
Examinations and Blood Biochemistry Parameters and NAFLD: A
Retrospective Study on 1994 Cases Observed at Shuguang
Hospital, China
Zhengli Tang
Shanghai University of Traditional Chinese Medicine

Minh Pham
University of South Florida

Yiming Hao
Shanghai University of Traditional Chinese Medicine

Fang Wang
Shanghai University of Traditional Chinese Medicine

Devashru Patel
Georgia Institute of Technology
Follow this and additional works at: https://digitalcommons.usf.edu/mth_facpub
See next page for additional authors

Scholar Commons Citation
Tang, Zhengli; Pham, Minh; Hao, Yiming; Wang, Fang; Patel, Devashru; Jean-Baptiste, Lori; Fan, Lin; Wang,
Weijian; Wang, Yiqin; and Cheng, Feng, "Sex, Age, and BMI Modulate the Association of Physical
Examinations and Blood Biochemistry Parameters and NAFLD: A Retrospective Study on 1994 Cases
Observed at Shuguang Hospital, China" (2019). Mathematics and Statistics Faculty Publications. 63.
https://digitalcommons.usf.edu/mth_facpub/63

This Article is brought to you for free and open access by the Mathematics and Statistics at Digital Commons @
University of South Florida. It has been accepted for inclusion in Mathematics and Statistics Faculty Publications
by an authorized administrator of Digital Commons @ University of South Florida. For more information, please
contact scholarcommons@usf.edu.

Authors
Zhengli Tang, Minh Pham, Yiming Hao, Fang Wang, Devashru Patel, Lori Jean-Baptiste, Lin Fan, Weijian
Wang, Yiqin Wang, and Feng Cheng

This article is available at Digital Commons @ University of South Florida: https://digitalcommons.usf.edu/
mth_facpub/63

Hindawi
BioMed Research International
Volume 2019, Article ID 1246518, 7 pages
https://doi.org/10.1155/2019/1246518

Research Article
Sex, Age, and BMI Modulate the Association of Physical
Examinations and Blood Biochemistry Parameters and NAFLD:
A Retrospective Study on 1994 Cases Observed at Shuguang
Hospital, China
Zhengli Tang,1 Minh Pham,2 Yiming Hao ,3 Fang Wang,1 Devashru Patel,4
Lori Jean-Baptiste ,5 Lin Fan,1 Weijian Wang ,1 Yiqin Wang ,3 and Feng Cheng

6

1

Shuguang Hospital Health Examination Center aﬃliated with Shanghai University of Traditional Chinese Medicine,
Shanghai 201203, China
2
Department of Mathematics and Statistics, College of Arts and Sciences, University of South Florida, Tampa, FL 33620, USA
3
Shanghai Key Laboratory of Health Identiﬁcation and Assessment/Laboratory of Traditional Chinese Medicine For Diagnostic
Information, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
4
College of Computing, Georgia Institute of Technology, Atlanta, GA 30332, USA
5
Biomedical Sciences Program, College of Arts and Sciences, University of South Florida, Tampa, FL 33620, USA
6
Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA
Correspondence should be addressed to Weijian Wang; wwjhxj@163.com, Yiqin Wang; wangyiqin2380@sina.com,
and Feng Cheng; fcheng1@health.usf.edu
Received 1 April 2019; Revised 8 May 2019; Accepted 9 June 2019; Published 24 June 2019
Academic Editor: Elena Grasselli
Copyright © 2019 Zhengli Tang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. Previous studies have shown that some metabolic risk factors are related to nonalcoholic fatty liver disease (NAFLD).
This retrospective study was performed to investigate the associations between physical examinations and blood biochemistry
parameters and NAFLD status and to identify possible risk factors of NAFLD. Methods. Study participants underwent general
physical examinations, blood biochemistry, and abdominal ultrasound evaluations. In addition, data regarding sex, age, ethnicity,
medical history, and alcohol consumption of participants were recorded. Among the study participants (N=1994), 57.8% were
male, 41.2% over the age of 50, and 52.6% with BMI≥24. 986 patients had NAFLD and 1008 had no NAFLD. We used effect size
analysis and logistic regression to determine which physical examinations and blood biochemistry parameters were significant
for the association between these parameters and NAFLD status. Results. Both the effect size and logistic regression indicated
that BMI, diastolic blood pressure (DBP), triglycerides (TG), and serum uric acid (SUA) show a significant association with
NAFLD. Females are overall at a higher risk of NAFLD, but factors such as high BMI, DBP, TG, and SUA increase the associated
risk for both sexes. Compared with males, females have a higher risk of NAFLD given that they are over 50, overweight and
obese (BMI at or over 24), or have high SUA. In terms of age, people older than 50 with high SUA, and people younger than
50 with high DBP and low-density lipoprotein cholesterol (LDL-C) all increase the risk of NAFLD. For BMI, high DBP and low
high-density lipoprotein cholesterol (HDL-C) are risk factors for NAFLD in overweight and obese people (BMI at or over 24),
whereas in normal weight and underweight people (BMI under 24), elevated LDL-C increases the risk of NAFLD. Conclusions.
Our results revealed sex, age, and BMI modulate the association of physical examinations and blood biochemistry parameters
and NAFLD, which may facilitate the development of personalized early warning and prevention strategies of NAFLD for at-risk
populations.
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is a multifactorial
disease, which is influenced by genetic factors as well as diet,
exercise, and lifestyle habits. NAFLD can increase the risk
of other liver diseases including nonalcoholic steatohepatitiscirrhosis (NASH-cirrhosis) and NASH-hepatocellular carcinoma (NASH-HCC) [1]. Recent studies also showed that
NAFLD was associated with increased risk of cardiovascular
disease, chronic kidney disease, and colorectal neoplasm [2–
4].
In recent years, NAFLD is common not only in developed
countries, but also in developing countries and is therefore a
global, rather than regional, public health issue [5–7]. Therefore, greater significance is being placed on early diagnosis
and treatment of NAFLD, which could prevent or diminish
morbidity and mortality associated with NAFLD.
It is widely accepted that there is a bidirectional relationship between NAFLD and various components of metabolic
syndrome, particularly hyperglycemia and hypertension [1].
Obesity, excessive intake of simple sugars, and physical
inactivity are also considered to be the dominant risk factors
of NAFLD [8, 9]. Previous studies have shown that some
physical examinations and blood biochemistry parameters
are associated with NAFLD [10–13]. However, confounding
factors such as sex, age, and obesity status may affect the
accuracy of association models because they are closely
associated with NAFLD [14–16]. The risk factors of NAFLD
may vary in female and male, as well as in different age
or body mass index (BMI) groups [17–20]. In this paper,
we not only investigated the association between general
physical examinations and blood biochemistry parameters
and NAFLD status, but also estimated the effects of sex, age,
and BMI on the association. This study will help identify risk
factors and lead to better NAFLD prediction models.

2. Materials and Methods
2.1. Data Source. Our data were collected from participants
(between 18 and 87 years old) who went through physical
examinations in the Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine from March
2017 to February 2018.
2.2. NAFLD Diagnosis and Criteria for Inclusion and Exclusion. The diagnosis of NAFLD was based on the presence of
steatosis after excluding competing causes of steatogenic liver
disease including
(a) Significant alcohol consumption (more than 7 standard alcoholic drinks/week (70 g ethanol) in women, more
than 14 (140 g) in men)
(b) Viral hepatitis caused by hepatitis A virus, hepatitis B
virus, hepatitis C virus, hepatitis D virus, and hepatitis E virus
based on serum test
(c) Drug-induced liver disease, including herbal
medicines and dietary supplements
(d) Autoimmune liver disease based on clinical manifestations, inquiries and consulting of medical history, and
abdominal color ultrasound, including autoimmune hepatitis
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(3 subtypes), celiac disease, primary biliary cholangitis, and
primary sclerosing cholangitis
(e) Diagnosis of metabolic liver disorders based on
clinical manifestations, inquiries and consulting of medical history, including Wilson’s disease, alpha-1-antitrypsin
deficiency, hemochromatosis, glycogen storage disorders,
cholesterol storage disorders, etc.
The criteria for NAFLD inclusion were established
according to the practice guideline of the diagnosis and
management of NAFLD [21].
2.3. Study Design and Data Collection. A retrospective study
was performed to investigate the association of physical examinations and blood biochemistry parameters and
NAFLD status in adults. All participants underwent physical
examinations, blood biochemistry, and abdominal ultrasound evaluations. In addition, data on sex, age, ethnicity,
medical history, and alcohol consumption were recorded.
Anthropometric data were measured using standard
methods published by the World Health Organization [22].
The BMI was calculated as body weight divided by height
squared (kg/m2 ). According to the criteria recommended by
National Health and Family Planning Commission of PRC
[23], BMI<18.5 refers to underweight, 18.5≤BMI<24 refers
to normal weight, 24≤BMI<28 refers to overweight, and
BMI≥28 refers to obese. Blood pressure was measured using
a mercury sphygmomanometer in a seated position after a 5minute rest and was recorded as the mean of two different
measurements taken within a 1-minute interval. A fasting
blood sample was collected from each participant via the
antecubital vein in the morning. Glucose (including FPG and
HbA1c), serum lipids (including TC, TG, LDL-C, and HDLC), indicators of liver function (including ALT, AST, and 𝛾GT), and indicators of kidney function (including SUA, SCr,
and eGFR) were measured in the hospital laboratory according to routine procedures. In the same day, the participants’
condition of NAFLD was judged by abdominal ultrasound
evaluations.
The data collected includes 1994 individuals, 1152 of
whom are male, 842 are female, 821 are 50 years old or older,
1173 are less than 50 years old, 945 are with BMI under 24, and
1049 are with BMI at or over 24. 986 patients were diagnosed
with NAFLD and 1008 without NAFLD as controls.
2.4. Statistical Analysis. We used logistic regression to determine risk factors for having fatty liver for all patients and for
each stratum (female versus male, older than 50 versus less
than 50, and normal weight & underweight versus overweight
& obese). Logistic regression has two important assumptions,
linear relationship between the log odds of the outcome and
the predictors and no multicollinearity between predictors.
We first plotted the log odds of the outcome against each
of the predictors to verify the first assumption. To prevent
multicollinearity in the model, we selected variables for the
models using the following process. First, we calculate the
Variance Inflation Factor (VIF) for each variable given all
other variables in the model. Then, the variable with the
highest VIF is discarded and we recalculate the VIFs. These
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two steps are repeated until all the VIFs are lower than 3. The
factors with p-value lower than 0.01 are considered significant
risk factors and are highlighted in the tables.
We performed the logistic regression models by using R
version 3.5.0 and the VIF calculations were done with the
“car” library.
2.5. Ethics Approval. The study was approved by the Ethics
Committee of Shanghai University of Traditional Chinese
Medicine and was performed in accordance with the Declaration of Helsinki. All the subjects signed informed consent
forms verifying consent and compliance.

3. Results
3.1. Comparison of NAFLD vs. Controls. Table 1 is a summary
of the physical examinations and blood biochemistry parameters and demographic data of the sample population. We
compared the control group with the NAFLD group by quantifying the effect size (Cohen’s d). Based on magnitudes of
Cohen’s d, these factors can be divided into three groups, large
(Cohen’s d≥0.8), medium (0.8>d≥0.5), and small (d<0.5)
effect size. Only there is a large difference in BMI values
between control and NAFLD groups. Some factors (such
as DBP, TG, HDL-C, SUA, ALT, and 𝛾-GT) show medium
differences between these two groups.
3.2. The Logistic Regression Models for All Individuals. To
identify possible risk factors of fatty liver, we also performed
a logistic regression analysis to investigate the association
between the fatty liver occurrence with demographic or
physical examinations and blood biochemistry parameters
for all 1994 individuals (Table 2). ALT, AST, and 𝛾-GT were
excluded from the model because the increase of these liver
function parameters could be the results of NAFLD. As
shown in the table, factors including BMI, DBP, TG, and
SUA show a very significant association with the fatty liver
occurrence (P<0.01), which is consistent with the effect size
calculation. The signs of the coefficients show that an increase
in BMI, DBP, TG, and SUA are associated with the occurrence
of NAFLD.
Sex Diﬀerence. As shown in Table 2, the p-value and positive
coefficient for sex indicate that females are more likely to have
NAFLD than males. In addition, the risk factors of NAFLD
may be different between male and female. To investigate the
sex difference in NAFLD, two logistic regression models were
performed for 1152 male and 842 females, respectively, which
can reveal how the significance of certain factors changed in
accordance with sex. The results were shown in Table 3. The
coefficients and p-values of the models indicate that factors
(BMI, DBP, and TG) which are significant (P<0.01) for men
all tend to be significant for women as well. It is noted that
SUA level shows significance in female (P=0.0002) instead of
male (P=0.26).
Age Diﬀerence. Splitting the data into two different age groups
can similarly show how factors are differently associated with
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NAFLD in the young (age<50) and the old group (age≥50).
Table 4 shows the logistic regression model results for 821
patients 50 years of age or older and 1173 patients under 50.
As shown in Table 4, BMI and TG are common significant
factors for the young and old groups. Younger patients
benefit significantly from low DBP and LDL-C levels as well.
However, DBP and LDL-C do not significantly affect older
individuals. Instead, it should be noted that for patients over
50, one is significantly more likely to have NAFLD if they are
female as well as have high SUA or eGFR.
Obesity Eﬀects. Both effective size and logistic regression
analysis indicate that BMI are significantly associated with
NAFLD. To investigate the relationship between BMI and
NAFLD, two separate logistic regression models were performed for normal weight and underweight (BMI under 24,
n=945) and overweight and obese people (BMI at or over
24, n=1049). The results are summarized in Table 5. TG and
SUA are common significant factors for the two groups. High
levels of LDL-C are associated with the chance of NAFLD for
those with a BMI under 24. Overweight and obese people are
more likely to have the disease if they had high DBP, eGFR,
or low HDL-C. They also tend to be more at risk if they are
female.

4. Discussion
In this retrospective study, we collected physical examinations and blood biochemistry parameters, other factors
such as sex, age, and obesity status, and investigated the
associations between these factors and NAFLD. This is the
first study to analyze the effect of sex, age, and BMI on the
association between physical examinations and blood biochemistry parameters and NAFLD status. From the results,
we observed the following important findings.
First, DBP and SUA are identified to be associated with
NAFLD by both effect size (Table 1) and logistic regression
(Table 2). And researchers also have observed that people
with high blood pressure have higher risk of NAFLD [24, 25],
which is consistent with our findings.
SUA level is clinically associated with many diseases
including metabolic diseases [26]. Three meta-analyses
showed that people in the highest level of SUA had an
exacerbated risk of NAFLD occurrence and the increased risk
is probably independent of conventional NAFLD risk factors
[27–29]. In our results, SUA has significant association with
NAFLD and especially for women. A similar study indicated
that the independent effect of hyperuricemia on NAFLD was
stronger in women than in men [30].
Second, we show here that sex is associated with NAFLD.
Some researchers found that males are more susceptible
to NAFLD [31, 32]. But in those studies, the male group
was compared to premenopausal women [33], who have a
high level of estrogen which protects them from NAFLD
[34]. When age was considered in a South China study, the
incidence rates of fatty liver disease in women over 50 years
old are higher than that in men, because women are no
longer protected by estrogen as they were advanced in age
[35]. In our research, the logistic regression model showed
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Table 1: Differences of demographic and physical examinations and blood biochemistry parameters between control (n=1008) and NAFLD
(n=986) groups.
Parameters
Sex, male (%)
Age (years)
BMI (kg/m2 )
SBP (mmHg)
DBP (mmHg)
TC (mmol/L)
TG (mmol/L)
LDL-C (mmol/L)
HDL-C (mmol/L)
FPG (mmol/L)
HbA1c (%)
SUA (𝜇mol/L)
SCr (𝜇mol/L)
eGFR (mL/min)
ALT (U/L)
AST (U/L)
𝛾-GT (U/L)

Control group
48%
45.61 ± 13.23
22.54 ± 2.58
124.26 ± 18.35
76.59 ± 10.65
4.94 ± 0.9
1.23 ± 0.75
2.82 ± 0.77
1.43 ± 0.34
5.11 ± 0.97
5.36 ± 0.72
331.88 ± 86.09
70.47 ± 15.85
103.17 ± 17.75
19.56 ± 12.7
21.61 ± 9.31
25.24 ± 21.81

NAFLD group
52%
48.27 ± 11.47
26.31 ± 3.29
133.11 ± 17.51
83.35 ± 10.32
5.16 ± 0.96
2.12 ± 1.48
3.03 ± 0.78
1.23 ± 0.37
5.52 ± 1.24
5.62 ± 0.81
382.42 ± 90.25
72.69 ± 14.91
102.24 ± 17.42
31.09 ± 24.36
25.24 ± 12.43
40.49 ± 34.64

Effect Size (Cohen’s d)
N/A
0.21
1.28
0.49
0.64
0.24
0.76
0.27
0.56
0.37
0.34
0.57
0.14
0.05
0.59
0.33
0.53

Table 2: Results of the logistic regression model for all 1994 individuals.

(Intercept)
Age
BMI
SBP
DBP
TG
LDL-C
HDL-C
SUA
eGFR
FPG
HbA1c
Sex, female

Coefficient
-16.02
0.009842
0.4155
-0.00839
0.02882
0.6537
0.1622
-0.3463
0.002622
0.009062
0.1848
0.01698
0.559

Standard error
1.096
0.005973
0.02601
0.004899
0.008061
0.0839
0.07728
0.1919
0.000854
0.00399
0.08063
0.1127
0.1498

z score
-14.611
1.648
15.97
-1.712
3.575
7.791
2.099
-1.805
3.072
2.271
2.292
0.151
3.732

p-value
< 2e-16
0.09938
< 2e-16
0.08698
0.00035
6.63E-15
0.03585
0.07111
0.00213
0.02314
0.02189
0.88021
0.00019

Table 3: Results of the logistic regression models for male (n=1152) and female (n=842) groups.

(Intercept)
Age
BMI
SBP
DBP
TG
LDL-C
HDL-C
SUA
eGFR
FPG
HbA1c

Coefficient
Male
Female
-13.2658
-20.2182
0.002213
0.026611
0.355822
0.539703
-0.01002
-0.01074
0.027274
0.039274
0.628818
0.76328
0.144987
0.101325
-0.35774
-0.13634
0.00116
0.00572
0.011235
0.006441
0.183773
0.120944
-0.00308
-0.00211

Standard error
Male
Female
1.344677
1.951553
0.006961
0.011978
0.032111
0.047346
0.006147
0.008632
0.010201
0.013805
0.093718
0.188619
0.099366
0.129806
0.229178
0.347107
0.001034
0.001547
0.005169
0.006578
0.103598
0.160726
0.161804
0.163338

Male
-9.865
0.318
11.081
-1.63
2.673
6.71
1.459
-1.561
1.123
2.174
1.774
-0.019

z score
Female
-10.36
2.222
11.399
-1.244
2.845
4.047
0.781
-0.393
3.698
0.979
0.752
-0.013

p-value
Male
< 2e-16
0.7505
< 2e-16
0.10306
0.00751
1.95E-11
0.14453
0.11853
0.26159
0.02974
0.07608
0.98484

Female
< 2e-16
0.026312
< 2e-16
0.213405
0.004443
0.000052
0.435046
0.694472
0.000218
0.32745
0.451758
0.989681
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Table 4: Results of the logistic regression models for young (age<50, n=1173) and old (age≥50, n=821) groups.

(Intercept)
BMI
SBP
DBP
TG
LDL-C
HDL-C
SUA
eGFR
FPG
HbA1c
Sex, female

Coefficient
< 50
≥ 50
-15.9682
-15.3334
0.457926
0.384688
-0.0169
-0.00435
0.042735
0.01892
0.564608
0.748372
0.288518
-0.05319
-0.56439
0.032413
0.001278
0.003663
0.003757
0.016959
0.121241
0.222519
0.169614
-0.07565
0.195866
0.945695

Standard error
< 50
≥ 50
1.448125
1.603174
0.036495
0.03862
0.008363
0.006014
0.012281
0.011256
0.106244
0.134605
0.107188
0.115621
0.239389
0.297334
0.001174
0.001254
0.005241
0.005917
0.129608
0.104029
0.170456
0.144627
0.217201
0.214469

z score
< 50
-11.03
12.548
-2.021
3.48
5.314
2.692
-2.358
1.089
0.717
0.935
0.995
0.902

≥ 50
-9.564
9.961
-0.724
1.681
5.56
-0.46
0.109
2.921
2.866
2.139
-0.523
4.409

p-value
< 50
≥ 50
< 2e-16
< 2e-16
< 2e-16
< 2e-16
0.043331
0.46931
0.000502
0.09281
1.07E-07
2.7E-08
0.007109
0.64548
0.018393
0.91319
0.27597
0.00349
0.473422
0.00415
0.349559
0.03244
0.319707
0.60092
0.367179
1.04E-05

Table 5: Results of the logistic regression models for normal & underweight (BMI<24, n=945) and overweight & obese (BMI≥24, n=1049)
groups.
Coefficient
(Intercept)
Age
SBP
DBP
TG
LDL-C
HDL-C
SUA
eGFR
FPG
HbA1c
Sex, female

< 24
-7.37867
0.020527
-0.00479
0.026534
0.721075
0.332423
-0.23655
0.003935
-0.00111
0.245978
-0.08415
0.174253

≥ 24
-6.76135
-0.00213
-0.00527
0.042591
0.712001
-0.02543
-0.68309
0.003483
0.013969
0.084616
0.2245
1.036711

Standard error
< 24
≥ 24
1.383066
1.24913
0.008716
0.007568
0.007151
0.006177
0.011578
0.010329
0.120035
0.112809
0.111361
0.102064
0.241765
0.244448
0.001277
0.001066
0.005999
0.005162
0.122277
0.122354
0.185368
0.169064
0.206224
0.207484

that among the individuals over 50 years old, females have
positive association (coefficient =0.20) with NAFLD instead
of males (Table 4). This positive association is not observed
in the individuals less than 50 years old. The phenomena can
be explained by the weaker protective effect of estrogen in
postmenopausal women. In addition, we found that obese
women are at higher risk of NAFLD, which is in line with
the conclusion of Bedossa’s group [36] and Lonardo’s group
[37].
Third, it was shown that high DBP, SUA, and LDL-C
have different effects on the risk of NAFLD in different age
groups. We noted that among the individuals under 50 years
old, high DBP increases the likelihood of having NAFLD.
The same positive association towards NAFLD is seen in
individuals over 50 years of age with high SUA. Another
interesting finding is that high LDL-C is a risk factor for
NAFLD among younger people (<50 years). These results
have not been reported by any other researchers.
Finally, in our results, people are more likely to have
NAFLD when they have higher BMI. This result is not
affected by age and sex. Obesity is one of the risk factors

z score
< 24
-5.335
2.355
-0.669
2.292
6.007
2.985
-0.978
3.082
-0.185
2.012
-0.454
0.845

p-value
≥ 24
-5.413
-0.282
-0.853
4.123
6.312
-0.249
-2.794
3.267
2.706
0.692
1.328
4.997

< 24
9.55E-08
0.01852
0.50343
0.02192
1.89E-09
0.00283
0.32786
0.00205
0.85311
0.04426
0.64984
0.39813

≥ 24
6.2E-08
0.77803
0.39376
3.73E-05
2.76E-10
0.80321
0.0052
0.00109
0.0068
0.48921
0.18421
5.84E-07

for NAFLD which has reached an agreement. This is also
consistent with the findings from both the elderly and the
youth [38, 39].
Dyslipidemia represents a key factor in NAFLD [40].
In this paper, TG, LDL-C, and HDL-C are the risk factors
of NAFLD. Individuals whose BMI is under 24 kg/m2 are
at increased risk in parallel with increasing levels of LDLC. Another study also showed that nonobese people with
higher LDL-C level within the normal range had an increased
cumulative incidence rate of NAFLD [41]. Our study also
indicates that overweight and obese individuals with low
HDL-C or high DBP have greater odds of having NAFLD
compared to individuals whose BMI is under 24. Although
the mechanism by which this occurs remains to be further
explored, it suggests that obese people should pay more
attention to the impact of changes in levels of HDL-C and
DBP.
In addition, the results show that the correlation between
eGFR and NAFLD is positive when people are older (over
50 years old) or overweight/obese (BMI at or over 24).
However, on the one hand, we find that eGFR in NAFLD
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group has no significant difference compared with normal
weight people. On the other hand, sex differences need to
be taken into account when calculating the eGFR value,
and the results of both male and female groups showed no
significant correlation. Therefore, the interpretation of eGFR
needs further verification.
There are some limitations in our research. First, some
known risk factors of demographic data for NAFLD, such as
dietary preferences, exercise habits, work types, and so on,
were not collected, which limits a comprehensive assessment
of the correlation between risk factors and NAFLD. Second,
the severity of NAFLD is not classified, and therefore the
impact of risk factors on NAFLD severity was unknown.
Third, we did not use a liver biopsy for NAFLD diagnosis,
although our noninvasive diagnostic method was more suitable for the survey methods applied here. Lastly, we are unable
to determine causal relationships due to the observational
nature of the study.
Nevertheless, our results show that sex, age, and BMI
have significant effects on the association between the physical examinations and blood biochemistry parameters and
NAFLD. Some of these effects are supported by current
literature, while others are novel. Our research demonstrates
several new populations that may be at risk for NAFLD
including people older than 50 with high SUA and people
younger than 50 with high DBP and LDL-C. High DBP and
low HDL-C are risk factors for NAFLD in people whose BMI
is at or over 24. Future prospective studies are needed to
confirm these effects, which will facilitate the development
of personalized early warning and prevention strategies for
NAFLD.
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